| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Pharmadrug Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.03 |
| 52 Week High | CA$0.075 |
| 52 Week Low | CA$0.025 |
| Beta | 2.91 |
| 1 Month Change | -25.00% |
| 3 Month Change | -14.29% |
| 1 Year Change | -57.14% |
| 3 Year Change | -95.71% |
| 5 Year Change | -97.96% |
| Change since IPO | -99.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHRX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -14.3% | -1.8% | -0.6% |
| 1Y | -57.1% | 50.8% | 3.9% |
Return vs Industry: PHRX underperformed the Canadian Pharmaceuticals industry which returned 50.8% over the past year.
Return vs Market: PHRX underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| PHRX volatility | |
|---|---|
| PHRX Average Weekly Movement | 25.6% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: PHRX's share price has been volatile over the past 3 months.
Volatility Over Time: PHRX's weekly volatility has decreased from 58% to 26% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Robert Steen | www.pharmadrug.ca |
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to vertically integrated elevate the use of functional mushrooms and psilocybin mushrooms.
Pharmadrug Inc. Fundamentals Summary
| PHRX fundamental statistics | |
|---|---|
| Market cap | CA$3.14m |
| Earnings (TTM) | CA$1.45m |
| Revenue (TTM) | n/a |
2.2x
P/E Ratio0.0x
P/S RatioIs PHRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHRX income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$8.00 |
| Gross Profit | -CA$8.00 |
| Other Expenses | -CA$1.45m |
| Earnings | CA$1.45m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 19.5% |
How did PHRX perform over the long term?
See historical performance and comparison